GlaxoSmithKline announces start of phase III study of Benlysta® (belimumab ) in patients with vasculitis

GlaxoSmithKline plc (GSK) today announced the start of a Phase III study to evaluate Benlysta® (belimumab) in patients with ANCA (Anti-neutrophil Cytoplasmic Antibodies) positive vasculitis – a condition that involves inflammation of the blood vessels.
Source: GSK news - Category: Pharmaceuticals Source Type: news